IL-5[Biotin], His & Avi, Human
IL-5[Biotin], His & Avi, Human

Immobilized Human IL-5 R alpha, hFc Tag at 2 μg/ml (100 μl/well) on the plate. Dose response curve for IL-5[Biotin], His & Avi, Human, His Tag with the EC50 of 68.2 ng/ml determined by ELISA.

IL-5[Biotin], His & Avi, Human

The purity of IL-5[Biotin], His & Avi, Human is greater than 95% as determined by SEC-HPLC.

IL-5[Biotin], His & Avi, Human

IL-5[Biotin], His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

IL-5[Biotin], His & Avi, Human

Human IL-5 R alpha, His Tag immobilized on CM5 Chip can bind IL-5[Biotin], His & Avi, Human, His-Avi Tag with an affinity constant of 7.57 nM as determined in SPR assay (Biacore T200).

IL-5[Biotin], His & Avi, Human

IL-5 is an important cytokine for priming and survival of mature eosinophils and for proliferation and maturation of their progenitors. IL-5(Rα) targeting will be increasingly used in diseases where eosinophils are the key immune effector cells such as eosinophilic asthma (EA), hypereosinophilic syndrome (HES), eosinophilic esophagitis (EE), and eosinophilic granulomatosis with polyangiitis (EGPA).
Z04515
¥123,118.00

Ask us a question
Product Introduction
Species Human
Protein Construction
Avi His IL-5 (Ile20-Ser134)
Accession # P05113
N-term C-term
Conjugate Biotin
Purity > 95% as determined by Bis­Tris PAGE 
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA.Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 16.1 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 18-25 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.

Examples
  • IL-5[Biotin], His & Avi, Human
    • IL-5[Biotin], His & Avi, Human

    Immobilized Human IL-5 R alpha, hFc Tag at 2 μg/ml (100 μl/well) on the plate. Dose response curve for IL-5[Biotin], His & Avi, Human, His Tag with the EC50 of 68.2 ng/ml determined by ELISA.

  • IL-5[Biotin], His & Avi, Human
    • IL-5[Biotin], His & Avi, Human

    The purity of IL-5[Biotin], His & Avi, Human is greater than 95% as determined by SEC-HPLC.

  • IL-5[Biotin], His & Avi, Human
    • IL-5[Biotin], His & Avi, Human

    IL-5[Biotin], His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

  • IL-5[Biotin], His & Avi, Human
    • IL-5[Biotin], His & Avi, Human

    Human IL-5 R alpha, His Tag immobilized on CM5 Chip can bind IL-5[Biotin], His & Avi, Human, His-Avi Tag with an affinity constant of 7.57 nM as determined in SPR assay (Biacore T200).


Background
Target Background IL-5 is an important cytokine for priming and survival of mature eosinophils and for proliferation and maturation of their progenitors. IL-5(Rα) targeting will be increasingly used in diseases where eosinophils are the key immune effector cells such as eosinophilic asthma (EA), hypereosinophilic syndrome (HES), eosinophilic esophagitis (EE), and eosinophilic granulomatosis with polyangiitis (EGPA).
Synonyms Interleukin-5; IL-5; T-cell replacing factor; TRF; EDF

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.